Journal of Zhejiang University SCIENCE B
ISSN 1673-1581(Print), 1862-1783(Online), Monthly

2007   Vol. 8   No. 7   p. 526~532

Synthesis and anticonvulsant activity of some potent 5,6-bis aryl 1,2,4-triazines

MALLIKARJUNA B.P.¹, SURESH KUMAR G.V.^†1, SASTRY B.S.², NAGARAJ ³, MANOHARA K.P.⁴

(¹Department of Medicinal Chemistry, St. Johns Pharmacy College, Bangalore-560040, Karnataka, India)
(²Department of Pharmaceutical Sciences, Andhra University, Visakhapatnam-530002, Andhra Pradesh, India)
(³Pharmacy Department, M.S. University, Baroda-390002, Gujarat, India)
(⁴Department of Pharmacognosy, Dr. H.L.T. College of Pharmacy, Bangalore-571502, Karnataka, India)
^†E-mail: gvsureshkumar@yahoo.com
Received Feb. 5, 2007 revision accepted Apr. 20, 2007

Abstract: In the present research, a series of 5,6-bis aryl 1,2,4-triazines 5a~5f were synthesized by condensation of various benzils 4a~4f with aminoguanidine bicarbonate and were screened in vivo, for their anticonvulsant and neurotoxicity studies. Compounds 5a, 5b and 5d were found to be potent molecules of this series, when compared with the reference drugs phenytoin sodium, diazepam and lamotrigine. The structures of these compounds were established by IR, ¹H NMR, ¹³C NMR and mass spectroscopic data.

Key words: 5,6-Bis aryl 1,2,4-triazines, Synthesis, Anticonvulsant activity
doi:10.1631/jzus.2007.B0526             CLC number: R914.5; TQ460.7+2

References:

[1] Chang, B.S., Lowenstein, D.H., 2003. Mechanisms of disease: epilepsy. N. Eng. J. Med., 349(13):1257-1262.

[2] Danny, D.S., René, H.L., Jill, L.S., Alan, V., 1992. Comparative anticonvulsant potency and pharmacokinetics of (+)- and (−)-enantiomers of stiripentol. Epilepsy Res., 1(11): 29-36.

[3] Dimmock, J.R., Sidhu, K.K., Tumber, D.F., 1995a. Some aryl semicarbazones possessing anticonvulsant activitie. Eur. J. Med. Chem., 30(4):287-301.

[4] Dimmock, J.R., Vashishtha, S.C., Stables, J.P., 1995b. Evaluation of the semicarbazones, thiosemicarbazones and bis-carbohydrazones of some aryl alicycylic ketones for anticonvulsant and other biological propertie. Eur. J. Med. Chem., 30(4):303-314.

[5] Duncan, J.S., 2002. The promise of new antiepileptic drugs. Br. J. Clin. Pharmacol., 53(2):123-131.

[6] Erickson, J.G., 1952. 3-Amino-as-triazines. J. Am. Chem. Soc., 74(18):4706.

[7] Fisher, R.S., 1989. Animal models of the epilepsies. Brain Research Reviews, 14(3):245-278.

[8] Grundmann, C., Kreutzberger, A., 1954. 1,3,5-Triazine. J. Am. Chem. Soc., 76(2):632-633.

[9] Hosford, D.A., Wang, Y., 1997. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia, 38(4):408-414.

[10] Kubicki, M., Codding, P.W., 2001. Hydrogen bonding patterns in 3,5-diamino-6-aryl triazines. Journal of Molecular Structure, 570(1-3):53-60.

[11] McNamara, J.O., 2001. Drugs Effective in the Therapy of the Epliepsies. In: Hardman, L.G., Limbird, L.E. (Eds.), Goodman and Gilman’s the Pharmacological Basis of Therapeutics. McGraw Hill, New York, p.521-547.

[12] Pandeya, S.N., Yogeswari, P., Stables, J.P., 2000. Synthesis and anticonvulsant activity of 4-bromophenyl substituted aryl semicarbazones. Eur. J. Med. Chem., 35(10):879-886.

[13] Pastalos, P.N., 1999. Synthesis of some oxime ether derivatives of 1-(2-naphthyl)-2-(1,2,4-triazol-1-yl)ethanone and their anticonvulsant and antimicrobial activities. Curr. Opin. CPNS Invest. Drugs, 1(64):549-555.

[14] Petroff, O.A., Rothman, D.L., Behar, K.L., Mattson, R.H., 1995. Initial observations on effect of vigabatrin on in vivo ¹H spectroscopic measurements of γ-aminobutyric acid, glutamate, and glutamine in human brain. Epilepsia, 36(5):457-464.

[15] Porsolt, R.D., Anton, G., Blavet, N., Jalfre, M., 1978. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol., 47(4):379-391.

[16] Richard, W.A., Peter, B.R., Theodre, J.F., 1972. Antimalarial activities of some 3,5-diamino-as-triazine derivatives. J. Med. Chem., 15(4):859-871.

[17] Sander, J.W.A.S., 1993. Some aspects of prognosis in the epilepsies: a review. Epilepsia, 34(6):1007-1016.

[18] Sawyer, D.A., Copp, F.C., 1992. Synthesis of novel triazoles as potent anticonvulsants. Chem. Abstr., 108:1125.

[19] Smith, Q.E., 1960. Pharmacological Screening Tests Progress in Medicinal Chemistry. 1: Butterworths. London, p.1-33.

[20] Stephani, U., 1989. The natural history of myoclonic astatic epilepsy the natural history of myoclonic astatic epilepsy. Epilepsia, 47(Suppl. 1):S53-S55.

[21] Taylor, C.P., 1996. Voltage-gated Na⁺ channels as targets for anticonvulsant, analgesic and neuroprotective drugs. Curr. Pharm. Des., 2(4):375-379.